Nordic Bioscience A/S has disclosed Wednesday that KKR & Co. (NYSE: KKR) has made an investment in the firm. The grant of KKR will be helpful for Nordic Bioscience and will help the firm with the marketing and the growth of its R&D services internationally. This financing will speed up the growth internationally.
It has been disclosed that KKR has provided a grant to Nordic through its Health Care Strategic Growth Fund. This fund is recognized as the notable fund which invested in the leading health care firms which have the potential. Since 2004, KKR has spent nearly $14 million in the health care sector.
KKR has financed in many firms and has helped firms in fulfilling their growth ambitions. It has a long history of assisting health care firms. Its main focus is health care growth and on teaming up with prominent firms to build and grown great business.
Nordic Bioscience holds more than 150 patents and has issued over 500 scientific papers in leading scientific journals. Nordic Bioscience has signed a collaboration agreement with the biggest pharma firms for the development of new drugs in four major stages. The four phases include fibrosis, oncology, diabetes, and cardiovascular.
Additionally, Nordic Bioscience facilitates an increasingly global customer base of pharma, biotech, and CROs with laboratory and clinical data assessment from its licensed laboratory. KKR believed that Nordic Bioscience has a strong concept of assisting sufferers internationally. Nordic has a skilled team and a unique scientific heritage. The investment in Nordic Bioscience is a great example of how KKR integrates its regional geographical franchises with profound understanding from its region squads.